End of Phase 2 meeting with the FDA and EMA expected in Q2 2024 and several biomarker study results anticipated as early as Q1 2024, as the Company advances partnership discussions
Statistically Significant Reduction in ALS Disease Progression in Phase 2b PARADIGM Trial
Top-line results in the Phase 2b PARADIGM trial of PrimeC revealed a statistically significant slowing of disease progression in ALS patients, compared to placebo. The study demonstrated a 37.4% (p=0.03) difference in the FDA-approved ALS functional rating scale revised (ALSFRS-R), compared to placebo, and a strong safety profile. These data highlight a novel approach to treating ALS, with potential implications in other...
Login or create a forever free account to read this news
Sign up/Log in